Treatment of Tardive Dyskinesia.
Neurol Clin
; 38(2): 379-396, 2020 05.
Article
en En
| MEDLINE
| ID: mdl-32279716
ABSTRACT
Tardive dyskinesia (TD) is an iatrogenic condition that encompasses a wide phenomenological spectrum of movement disorders caused by exposure to dopamine receptor blocking agents (DRBAs). TD may cause troublesome or disabling symptoms that impair quality of life. Due to frequent, often inappropriate, use of DRBAs, TD prevalence rates among patients exposed to DRBAs continue to be high. The judicious use of DRBAs is key to the prevention of TD, reduction of disease burden, and achieving lasting remission. Dopamine-depleting vesicular monoamine transporter type 2 inhibitors are considered the treatment of choice of TD.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Discinesia Tardía
Tipo de estudio:
Qualitative_research
/
Risk_factors_studies
Aspecto:
Patient_preference
Límite:
Humans
Idioma:
En
Revista:
Neurol Clin
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos